We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · October 04, 2017

Pioglitazone After Stroke or TIA Is More Beneficial for Those at Higher Risk for Stroke or MI

JAMA Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Neurology
Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction
JAMA Neurol 2017 Sep 18;[EPub Ahead of Print], WN Kernan, CM Viscoli, JL Dearborn, et al

Further Reading